8,322 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Lbp Am Sa

Key Points

• Lbp Am Sa has purchased 8,322 shares of Alnylam Pharmaceuticals, valued at approximately $2.7 million, marking a new position in the biopharmaceutical company.
• Alnylam Pharmaceuticals reported an EPS of $0.32 for the last quarter, significantly beating analysts' estimates of ($0.54), with revenue increasing by 17.3% year-over-year to $773.69 million.
• Several analysts have raised their price targets for Alnylam Pharmaceuticals, with Barclays setting a new objective of $460, reflecting growing confidence in the company's prospects.

Lbp Am Sa acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 8,322 shares of the biopharmaceutical company's stock, valued at approximately $2,714,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bessemer Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $275,000. Strs Ohio purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $7,781,000. GAMMA Investing LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 14.3% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after purchasing an additional 77 shares in the last quarter. Finally, Brighton Jones LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $243,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 31,448 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director owned 911 shares in the company, valued at approximately $397,724.38. This represents a 97.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the transaction, the director owned 16,804 shares in the company, valued at $7,561,800. This trade represents a 40.10% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,594 shares of company stock worth $33,968,256. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.1%

ALNY opened at $460.99 on Friday. The business has a 50 day simple moving average of $439.02 and a two-hundred day simple moving average of $337.29. The firm has a market capitalization of $60.43 billion, a price-to-earnings ratio of -186.64 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals's quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

ALNY has been the subject of a number of research reports. Barclays upped their price objective on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Wells Fargo & Company boosted their target price on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. The Goldman Sachs Group boosted their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a "buy" rating in a research note on Tuesday, September 16th. Jefferies Financial Group boosted their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th. Finally, Scotiabank boosted their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $439.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.